{"schema_version":"secwatch.filing_event.v1","accession":"0001804220-24-000006","form_type":"8-K","ticker":"REGN","cik":"0000872589","company_name":"REGENERON PHARMACEUTICALS, INC.","filed_at":"2024-02-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:27.097167+00:00","generated_at":"2026-06-06T10:24:50.421983+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Regeneron Q4 revenues $3.43B (+1% YoY); Dupixent up 31%; full-year guidance issued","bullets":["Q4 GAAP EPS $10.19, non-GAAP $11.86; FY GAAP EPS $34.77, non-GAAP $43.79.","Dupixent global net sales Q4 $3.22B (+31% YoY), FY $11.59B (+33%). EYLEA franchise U.S. net sales down 2% in Q4.","Pipeline: Dupixent COPD sBLA and linvoseltamab BLA submitted; EYLEA HD approved in EU/Japan.","FY2024 guidance: GAAP R&D $4.82-5.07B, SG&A $2.89-3.09B, gross margin 86-88%.","Share repurchases $2.215B in FY2023; $1.5B remain. CFO Robert Landry to retire."],"urls":{"canonical":"https://secwatch.observer/filing/0001804220-24-000006","json":"https://secwatch.observer/filing/0001804220-24-000006.json","markdown":"https://secwatch.observer/filing/0001804220-24-000006.md","text":"https://secwatch.observer/filing/0001804220-24-000006.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/872589/000180422024000006/0001804220-24-000006-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/872589/000180422024000006/regn-20240202.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T10:24:50.421983+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"dca6759d2cb07ceb455171ed55f3067cbad693cb","claim":"REGENERON PHARMACEUTICALS, INC. reported the quarter and year ended December 31, 2023 results: revenue $3.43 billion (Q4 2023), $13.12 billion (Full year 2023), net income $1,160 million (Q4 2023 GAAP), $3,954 million (Full year 2023 GAAP), EPS $10.19 per diluted share (Q4 2023 GAAP), $34.77 per diluted share (Full year 2023 GAAP).","evidence_excerpt":"On February 2, 2024, Regeneron Pharmaceuticals, Inc. issued a press release announcing its financial and operating results for the quarter and year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/872589/000180422024000006/0001804220-24-000006-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter and year ended December 31, 2023"},{"label":"Revenue","value":"$3.43 billion (Q4 2023), $13.12 billion (Full year 2023)"},{"label":"Net income","value":"$1,160 million (Q4 2023 GAAP), $3,954 million (Full year 2023 GAAP)"},{"label":"EPS","value":"$10.19 per diluted share (Q4 2023 GAAP), $34.77 per diluted share (Full year 2023 GAAP)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}